Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online CNE evaluation.
Speaker, Faculty, Planners and Authors Conflict of Interest Disclosure: Speaker(s) have no disclosures to declare.
Planning Committee: • Annette Hood discloses that she is a member of the Amgen speakers’ bureau. • Denise Murcek discloses other financial/material support as an employee of the VA Medical Center. • Elizabeth St. John discloses other financial/material support as an employee of Fresenius Medical Care. • Kyra Trappett discloses other financial/material support as an employee of DaVita.
Commercial Support and Sponsorship: No commercial support or sponsorship declared.
Accreditation Statement: American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.
Objectives: • Review the epidemiologic association of uric acid and progression of CKD and CVD. • Discuss the mechanisms by which uric acid causes vascular damage. • Determine why patients with CKD have elevated uric acid. • Analyze clinic trial data on the efficacy of uric acid lowering therapy to treat or prevent hypertension, CKD, and cardiovascular disease.